PDCD1 and non-small cell lung carcinoma: The same combination is being evaluated in a phase 1/2 trial (ClinicalTrials.gov, NCT03367819) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients who are naive to anti-PD-1/PD-L1 therapy and NSCLC patients who progressed on prior anti-PD-1/PD-L1 therapy.